OBJECTIVE: To investigate the effect of glucocorticoid administration on leptin in humans. DESIGN: A 30 min IV infusion of methylprednisolone (METH, 125 mg) or placebo (PLAC) followed by 4 d of oral administration of METH (40 mg/d) or PLAC. Fasting plasma glucose, free-fatty acids (FFA), insulin and leptin concentrations were measured at baseline, 210 min after the beginning of the IV infusion and after 4 d of oral treatment. SUBJECTS: Twenty healthy non-diabetic male volunteers (27 AE 5 y, 72 AE 9 kg, 20 AE 7% body fat; means AE s.d.) fed a weight maintenance diet and randomly assigned to METH (n 10) or PLAC (n 10) treatment. RESULTS: At baseline, leptin was positively correlated with % body fat in the 20 subjects (r 0.53; P`0.02). Acute METH administration signi®cantly increased fasting plasma glucose (P`0.01), but had no effect on insulin, FFA or leptin concentrations as compared to PLAC. Prolonged METH administration signi®cantly increased fasting plasma insulin P`0.05), but had no effect on glucose, FFA or leptin concentrations as compared to PLAC. CONCLUSION: These data suggest that in relatively lean individuals, the administration of therapeutic doses of methylprednisolone does not change plasma leptin concentration.
Introduction
In the ob/ob mouse obesity results from a genetic mutation that prevents the production of leptin by the adipocyte. 1 The administration of this protein reduces food intake and increases energy expenditure thus inducing weight loss in these animals. 2±4 In humans, leptin is secreted by the adipose tissue in proportion to the degree of adiposity. 5, 6 There is however some variability in leptin concentrations among individuals with comparable degrees of obesity, 5 indicating that other factors in¯uence plasma leptin concentrations. It has recently been suggested that hormones such as insulin and cortisol, which also participate in the regulation of energy balance, may modulate the production of leptin by the adipocyte.
The relationship between insulin and leptin appears to be complex. Recent studies in adipocytes cell lines and in animal models of obesity have shown that insulin stimulates leptin gene expression. 7±10 This is only partly supported by human clinical studies. Short term studies indicate a dissociation between changes in leptin and insulin concentrations. 11 In contrast, hyperinsulinemia maintained over a longer period of time results in increased leptin production in humans. 12 Kolaczynsky et al 12 suggested that, rather than a direct effect on OB gene expression, the observed long term effect of insulin on leptin might be secondary to a trophic effect of the latter hormone on adipocytes.
Preliminary information in animals seems to indicate a stimulatory effect of glucocorticoids on ob gene expression and leptin production. 13±15 Leptin has been shown to blunt the starvation-induced increase in adrenal activity in mice, 16 thus suggesting a possible feed back regulatory loop between adipose tissue and hypothalamus-pituitary-adrenal axis. Glucocorticoids are known to promote obesity (mainly via increased energy intake) 17 and induce insulin resistance and hyperinsulinemia 18 in humans. If the orexigenic effect of glucocorticoids was mediated by leptin, one would predict, in contrast with data in animals, a reduction of leptin concentration in response to glucocorticoid administration. To test this, we measured plasma leptin concentration in twenty healthy volunteers before and after acute and prolonged administration of glucocorticoids or placebo.
Methods

Subjects
Twenty, young, relatively lean non-diabetic male volunteers from the greater Phoenix area participated in a previously published study of the effect of glucocorticoids on energy metabolism. 17 Subjects were determined to be in good health by medical history, physical examination, and laboratory screening tests and were admitted for approximately one week to the CRC of the Clinical Diabetes and Nutrition Section of the National Institutes of Diabetes and Digestive and Kidney Diseases. Upon admission, all subjects were placed on a weight-maintenance diet (50% carbohydrate, 30% fat, 20% protein) calculated on the basis of body weight and adjusted to maintain body weight within 1%.
Experimental protocol
Body composition was assessed by dual-energy X-ray absorptiometry. Subjects were assigned to the drug (n 10) or placebo (N 10) treatment in a doubleblind fashion according to a predetermined randomization scheme. The drug used was methylprednisolone, a synthetic steroid molecule with a glucocorticoid relative potency of $ 6 and no mineralocorticoid potency. The methylprednisolone doses used in the present study were chosen from the medium-high range of therapeutical use and should therefore be considered in the pharmacological range. At least 3 d after admission and after an overnight fast, subjects received a 30 min IV infusion of methylprednisolone (125 mg diluted in 500 cc of saline) or saline (500 cc). The 10 subjects randomized to the IV treatment with glucocorticoids, received a 16 mg tablet of methylprednisolone in the evening of the same day. For the following 3 d, methylprednisolone was administered orally at a dose of 40 mg/d (24 mg at 0800 h/ 16 mg at 2000 h). The other 10 subjects received placebo pills. The protocol was approved by the Institutional Review Board of the NIDDK and written, informed consent was obtained from all subjects.
Blood samples and analytical procedures
Fasting plasma glucose, free fatty acids (FFA), insulin and leptin concentrations were measured at baseline (average value from two samples collected before the IV infusion), 210 min after the beginning of the IV infusion and after 4 d of oral treatment. Plasma glucose concentrations were measured by the glucose oxidase method (Beckman Glucose Analyzer Fullerton, CA), insulin concentrations by radioimmunoassay (Concept 4; ICN Biomedicals, Costa Mesa, CA), and FFA concentrations by enzymatic micro¯uorime-try. 19 Leptin concentrations were measured by an ELISA using immunopuri®ed anti-human leptin antibodies for trapping and detection. 5 
Statistical analysis
All values are expressed as means AE s.d. unless otherwise indicated. Statistical analyses were performed using STATGRAFIC 5.0. Plasma insulin and leptin concentrations were log 10 transformed prior to parametric analyses. Effect of methylprednisolone was tested by paired t-test on the differences in plasma FFA, glucose, insulin, and leptin concentrations between baseline and 210 min after the IV infusion or baseline and the 4th day of oral treatment. P value were considered signi®cant when`0.05.
Results
Subjects were 27 AE 5 y old, and weighed 72 AE 9 kg with 20 AE 7% of the body weight being fat. After randomization to methylprednisolone (METH, n 10) or placebo (PLC, n 10) treatment, the physical characteristics of the two groups were similar. At baseline, in the twenty subjects leptin was positively correlated with % body fat (r 0.53; P`0.02) but not with insulin, glucose or FFA plasma concentrations. After acute IV administration, plasma FFA concentrations increased similarly in both the placebo and METH group probably as a result of the prolonged fast (Table 1) . Plasma glucose concentrations increased in response to METH but not saline infusion thus revealing a treatment effect on glucose metabolism (P`0.01) ( Table 1 ). Acute METH administration had no effect on plasma insulin or leptin concentrations as compared to PLAC ( Table 1 ). The 4 d administration of METH signi®cantly increased fasting plasma insulin (P`0.05), but had no effect on plasma glucose, FFA or leptin concentrations as compared to PLAC (Table 2) . Signi®cantly different from 0: *P 0.10;**P`0.01. Signi®cantly different from placebo: ***P`0.05.
Discussion
The results of the present study indicate that the acute or prolonged administration of therapeutic doses of glucocorticoids to relatively lean individuals had no effect on plasma leptin concentration. It is worth noting that leptin concentration did not change even in the presence of a 3-fold increase in plasma insulin concentration in response to the 4 d glucocorticoid administration. Kolaczynsky et al 12 have recently shown that sustained hyperinsulinemia ( $ 150 U/ml for 3 d) under hyperglycemic conditions increased plasma leptin concentration. They suggested that this might be the consequence of a trophic effect of insulin on the adipocyte. In our series, however, the level of hyperinsulinemia attained was considerably less than that reported by Kolaczynsky et al, 12 and increased insulin concentration was probably secondary to the glucocorticoid-induced insulin resistance. 18 In vitro studies and experiments in animals have suggested that glucocorticoids may have a direct stimulatory effect on ob gene expression. 13±15 A stimulatory effect of cortisol on leptin secretion has also been observed in adipocytes from the mammary adipose tissue depot of healthy women. 10 Also, glucocorticoids reduce sympathetic nervous system activity when administered to humans. 17, 20, 21 Because catecholamines seem to inhibit ob gene expression, 22, 23 one would predict the glucocorticoids can indirectly stimulate leptin production via a removal of the SNS inhibitory tone. Our data, however, suggest that the stimulatory effect of glucocorticoids on leptin production observed in vitro in adipocyte culture or in vivo in experimental animals is not observed in humans. This is in constrasts with a recent preliminary report by Papaspyrou-Rao et al 24 showing that the administration of dexamethasone for 48 h to six overweight individuals increased leptin mRNA expression in subcutaneous abdominal and gluteal adipose tissue. Because of the differences in the physical characteristics of the subjects studied (lean vs moderately obese), duration of treatment (4 d vs 48 h), and synthetic glucocorticoid molecule used (methylprednisolone vs dexamethasone) the results of these two studies may, however, not be directly comparable.
If the well known orexigenic effect of glucocorticoids in humans 17 was mediated by leptin, one would predict a reduction of leptin concentration in response to acute or chronic glucocorticoid administration. This would be in line with the inhibitory effect of dexamethasone on leptin in 3T3 L1 adipocytes 25 and the reciprocal diurnal rhythms of cortisol and leptin in humans.
11 Because in our study plasma leptin concentration did not change in response to methylprednisolone administration, the glucocorticoid induced stimulation of food intake is unlikely to be mediated by a peripheral effect on the adipocyte. Instead, there is strong evidence that glucocorticoids may participate in the central regulation of appetite.
17,26
Conclusions
In humans, glucocorticoid administration has no effect on plasma leptin concentration and therefore the orexigenic effect of glucocorticoids is independent from changes in leptin production by the adipocyte. However, further investigation is warranted to understand whether or not these ®ndings are speci®c to lean individuals and/or to methylprednisolone administration. 
